Irreversible electroporation

AngioDynamics Completes Enrollment for PRESERVE Clinical Study

Retrieved on: 
Thursday, August 3, 2023
Science, Cardiology, Research, Oncology, General Health, Health, Medical Devices, Clinical Trials, Society, IRE, Partnership, University, Bureau of Oceans and International Environmental and Scientific Affairs, University of Michigan, British Association of Urological Surgeons, Cancer, Quality of life, Ablation, Irreversible electroporation, Death, Incidence, Nanoknife, Regeneration, MD, Patient, Memorial Sloan Kettering Cancer Center, American Cancer Society, Disease, Prostate cancer, Medical imaging

The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).

Key Points: 
  • The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).
  • "The PRESERVE study demonstrates AngioDynamics’ commitment to innovating care delivery,” said Juan Carlos Serna, AngioDynamics Senior Vice President of Clinical and Scientific Affairs.
  • We appreciate the support provided by our PRESERVE study sites and the partnership with the SUO-CTC team in this important effort.”
    Final patient enrollment in the study was initially announced during AngioDynamics’ Fiscal 2023 Fourth Quarter and Full-Year Financial Results conference call on July 12, 2023.
  • The PRESERVE study will have its primary endpoint analysis at 12 months following treatment.

Groundbreaking Results Using Canady Helios™ Cold Plasma Treatment Published in MDPI Journal “Cancers”

Retrieved on: 
Wednesday, August 2, 2023
Research, Technology, Medical Devices, Surgery, Health Technology, Biotechnology, Robotics, Health, Science, Oncology, Canady, Cell death, RNS, Histone, Survival, Clinical trial, Immunotherapy, CHCP, Irreversible electroporation, Plasma, ROS, Cancer, LRR, Patient, Sheba Medical Center, Reactive oxygen species, Apoptosis, Education minister, Cell division, FACS, Neoplasm, Rush University Medical Center, Recurrence, FDA, Reactive nitrogen species, Messenger, Pharmaceutical industry

It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.

Key Points: 
  • It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.
  • The recent trial reveals that treating the surgical margin following a tumorectomy significantly reduced local recurrence and increased overall survival.
  • CHCP opens a new and promising treatment for addressing the challenges of eradicating microscopic residual cancer cells following surgical tumor resection.
  • Jerome Canady, M.D., FACS, CEO stated, “We are very pleased to have our results published in the peer reviewed journal 'Cancers'.

JCRI-ABTS and USMI Reports Statistically Significant Results of the Canady Helios Cold Plasma Phase 1 Clinical Trial on Patients with Stage 4 and Recurrent Advanced Solid Tumors

Retrieved on: 
Thursday, June 15, 2023
Other Health, Research, General Health, Oncology, Medical Devices, Clinical Trials, Science, Surgery, Biotechnology, Alternative Medicine, FDA, Health, Anoxic waters, DNA, Radiation, IRE, Cell death, RNS, Safety, CAP, Survival, Cancer, Ovary, Breast, Global health, Reactive nitrogen species, Human embryonic stem cells clinical trials, Prostate, Treatment of lung cancer, Immunotherapy, CHCP, Messenger, Glioblastoma, ASCO, Irreversible electroporation, ROS, Sarcoma, SMC, Clinical trial, LRR, Patient, Risk, Melanoma, Sheba Medical Center, Plasma, Annual general meeting, Education minister, IDE, Rush University Medical Center, RUMC, Reactive oxygen species, Society, Medical imaging

(ClinicalTrials.gov identifier: NCT04267575)

Key Points: 
  • (ClinicalTrials.gov identifier: NCT04267575)
    Cancer remains a significant global health challenge, with over 1.9 million new cases and 608,570 cancer-related fatalities in the United States in 2021.
  • USMI’s Canady Helios Cold Plasma (CHCP) system, a non-thermal (26-30°C) and non-contact Cold Atmospheric Plasma (CAP) jet, offers a promising solution.
  • Twenty patients ranging from 26-85 years of age undergoing surgery for advanced stage 4 or recurrent solid tumors were enrolled.
  • Patients with preoperative treatments such as neoadjuvant chemotherapy, immunotherapy, radiation, and previous surgery were eligible.

Study demonstrates feasibility of hologram technology in liver tumor ablation

Retrieved on: 
Monday, June 15, 2020
Medicine, Medical specialties, Clinical medicine, Hepatology, Microwave ablation, Interventional radiology, Ablation, Liver tumor, Interventional oncology, Irreversible electroporation

In this initial in-human pilot study , the technology was used to deliver a treatment known as percutaneous thermal ablation of solid liver tumors.

Key Points: 
  • In this initial in-human pilot study , the technology was used to deliver a treatment known as percutaneous thermal ablation of solid liver tumors.
  • To apply this technology, interventional radiologists from the Cleveland Clinic use multi-phase CT to record coordinate markers placed on a patient's body.
  • The study included five patients who were selected for microwave ablation of their liver tumors.
  • Post-procedural imaging showed adequate tumor ablation, and nopatients experienced tumor recurrence at the three-month follow-up.

Late-Breaking Clinical Study Presented at AF Symposium 2020 Evaluates Attune Medical’s ensoETM For Use During Cardiac Ablation Procedures

Retrieved on: 
Thursday, January 30, 2020
Science, Cardiology, Biotechnology, Research, Health, FDA, Medical devices, Clinical trials, Medicine, Medical specialties, Clinical medicine, Catheter ablation, Esophageal cancer, Surgical oncology, Interventional radiology, Medical tests, Irreversible electroporation

The ensoETM is being evaluated in this and other studies to investigate the devices ability to reduce esophageal injury related to common ablation techniques.

Key Points: 
  • The ensoETM is being evaluated in this and other studies to investigate the devices ability to reduce esophageal injury related to common ablation techniques.
  • This study is the first randomized clinical trial to be presented and includes endoscopy-proven injury assessment to investigate the ensoETM to mitigate the risk of thermal injury complications.
  • The study compared fluoroscopy time required for 91 patients using standard luminal esophageal temperature monitoring to 189 patients treated with the ensoETM.
  • We are thrilled to support these key studies evaluating the ensoETM as a method for decreasing risk of esophageal injury in cardiac ablation.

Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus

Retrieved on: 
Monday, January 6, 2020
RTT, Medical specialties, Barrett's esophagus, Medicine, Esophageal cancer, Ablation, Clinical medicine, Cancer, Interventional radiology, Esophageal, Irreversible electroporation

RFA is typically known as a cancer preventative therapy that either delays or arrests the progression of Barretts Esophagus to esophageal cancer.

Key Points: 
  • RFA is typically known as a cancer preventative therapy that either delays or arrests the progression of Barretts Esophagus to esophageal cancer.
  • Evidence to date suggests that BarreGEN may identify non-dysplastic Barretts Esophagus patients in need of ablation, making targeted ablation a potentially cost-effective treatment option.
  • The study is a prospective, single site study which will be performed using BarreGEN and targeted to evaluate approximately 60 patients with dysplastic Barretts undergoing RFA.
  • The assay may also aid in recognition of patients at risk for recurrence of Barretts after initially successful ablation.

Outlook on the World's $1+ Billion Tumor Ablation Market, 2019-2024 - Minimally Invasive (MI) Procedures are Gaining Widespread Preference

Retrieved on: 
Monday, December 30, 2019
Medicine, Clinical medicine, Branches of biology, Medical physics, Plasma physics, Interventional radiology, Surgical oncology, Irreversible electroporation, Medical technology, High-intensity focused ultrasound, Ablation, Electroporation

The global tumor ablation market reached a value of US$ 538.7 Million in 2018.

Key Points: 
  • The global tumor ablation market reached a value of US$ 538.7 Million in 2018.
  • Also, various technological advancements such as the introduction of thermal and laser ablation, irreversible electroporation and High-Intensity Focused Ultrasound (HIFU) have enhanced the acceptance of tumor ablation procedures.
  • How has the global tumor ablation market performed so far and how will it perform in the coming years?
  • What is the degree of competition in the global tumor ablation industry?

Global Tumor Ablation Market Growth, Trends and Forecasts (2019-2024): Radiofrequency Ablation (RFA) to Witness the Highest CAGR - ResearchAndMarkets.com

Retrieved on: 
Monday, December 2, 2019
Health, Oncology, Medicine, Interventional radiology, Medical specialties, Clinical medicine, Surgical oncology, Medical terminology, Radiofrequency ablation, Ablation, Oncology, Microwave ablation, Irreversible electroporation

The "Tumor Ablation Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tumor Ablation Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • Radiofrequency ablation uses high-energy radio waves for treatment, in which a thin, needle-like probe is inserted into the tumor.
  • The tumor ablation market is consolidated and consists of the few major players.
  • With technological advancements, it is believed that new companies will enter the market in the coming future with their novel techniques.

Ongoing Clinical Studies Investigate Esophageal Injury Prevention During Cardiac Ablation Procedures Using Attune Medical’s ensoETM

Retrieved on: 
Thursday, November 21, 2019
Research, Medical devices, Surgery, FDA, Clinical trials, Cardiology, Biotechnology, Health, Science, Other Science, Medicine, Clinical medicine, Cardiac arrhythmia, RTT, Medical specialties, Atrial fibrillation, Ablation, Catheter ablation, Interventional radiology, Surgical oncology, Irreversible electroporation, Clinical cardiac electrophysiology

Chicago-based medical device firm Attune Medicals ensoETM is being evaluated in numerous ongoing clinical studies to investigate device efficacy in reducing thermal injury to the esophagus during cardiac ablation procedures, a common treatment for atrial fibrillation.

Key Points: 
  • Chicago-based medical device firm Attune Medicals ensoETM is being evaluated in numerous ongoing clinical studies to investigate device efficacy in reducing thermal injury to the esophagus during cardiac ablation procedures, a common treatment for atrial fibrillation.
  • It is the most common type of cardiac ablation procedure, with nearly 250,000 per year performed in the US and EU alone.
  • Several ongoing clinical studies are currently recruiting patients to investigate current prevention tools and effective mitigation strategies beyond current practice, including studies on the ensoETM.
  • Attune Medical is proud to support key studies around the world designed to evaluate new strategies to improve patient safety during cardiac ablation, commented Attune Medical CEO Keith Warner.

The global tumor ablation market size is anticipated to reach USD 2.41 billion by 2026

Retrieved on: 
Wednesday, October 30, 2019
Medicine, RTT, Clinical medicine, Medical specialties, Cryoablation, Ablation, Prostate cancer, Cancer, Breast cancer, Irreversible electroporation, Microwave ablation

Tumor Ablation Market Size, Share & Trends Analysis Report By Treatment (Surgical, Percutaneous), By Technology (Cryoablation, IRE, MWA, RFA), By Application (Liver, Lung, Breast, Prostate), And Segment Forecasts, 2019 - 2026

Key Points: 
  • Tumor Ablation Market Size, Share & Trends Analysis Report By Treatment (Surgical, Percutaneous), By Technology (Cryoablation, IRE, MWA, RFA), By Application (Liver, Lung, Breast, Prostate), And Segment Forecasts, 2019 - 2026
    The global tumor ablation market size is anticipated to reach USD 2.41 billion by 2026 The market is estimated to witness a healthy CAGR of 11.12% during the forecast period.
  • Increasing cases of cancer across the globe is the key growth-driving factor for this market.
  • About 13.0% of the population suffers from cancer each year, as per the statistics by the World Health Organization (WHO).
  • Sedentary lifestyle, increasing incidences of smoking and rising air pollution are contributing to the growing prevalence of lung cancer
    North America led the overall tumor ablation market.